Drug intelligence / Profile preview

11D7

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**11D7** is a novel neutralizing monoclonal antibody (mAb) discovered through mouse immunization and hybridoma generation targeting the receptor-binding domain (RBD) of the parental Wuhan-Hu-1 strain of SARS-CoV-2. It binds as a Class 4 RBD-binding mAb outside the ACE2 binding site, neutralizing the virus via a unique mechanism distinct from typical therapeutic mAbs, and retains activity against the Omicron (B.1.1.529) RBD. A chimeric human IgG version was recombinantly expressed in ΔXFT Nicotiana benthamiana plants, yielding human-like, highly homogenous N-linked glycans for enhanced potency and safety.[1]

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on 11D7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11D7.

Explore the full profile